A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs CC 90010 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 08 Sep 2017 Planned number of patients changed from 100 to 115.
- 08 Sep 2017 Planned End Date changed from 22 Apr 2022 to 15 Apr 2022.
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.